The latest research regarding Rituxan has been published in the New England Journal of Medicine
and the results are promising. Rituxan works by targeting B-cells, a specific type of immune cell. The optimism surrounding this treatment is based on its ability to precisely target a specific type of cell, perhaps paving the way for other "smart" treatments for joint diseases. Read about the latest research results for Rituxan.
UPDATE: On 03/01/2006, Rituxan (rituximab) was FDA approved to be used in combination with methotrexate to treat rheumatoid arthritis by reducing the signs and symptoms in adult patients who have moderately-to-severely active rheumatoid arthritis and have failed one or more anti-TNF drugs e.g. Enbrel (etanercept), Remicade (infliximab), or Humira (adalimumab).